Owlet to Report First Quarter 2025 Financial Results on May 8, 2025
LEHI, Utah--(BUSINESS WIRE)-- Owlet, Inc. ('Owlet' or the 'Company') (NYSE: OWLT) plans to announce first quarter 2025 financial results after market close on Thursday, May 8, 2025. Owlet's Chief Executive Officer and Co-Founder, Kurt Workman; President, Jonathan Harris; and Chief Financial Officer, Amanda Twede Crawford, will host a conference call at 4:30 p.m. ET the same day to discuss these results and provide a business update.
Participants may access the call at 833-470-1428 (domestic) or 404-975-4839 (international) and reference Access Code 952382. A simultaneous webcast may be accessed online at the Events section of Owlet's Investor Relations website at investors.owletcare.com. A replay will be available on the Investor Relations website shortly after the webcast concludes.
About Owlet, Inc.
Owlet's digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE: OWLT), a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.
Since 2012, over two million parents worldwide have used Owlet's platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life.
To learn more, visit www.owletcare.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
These stocks all pay more than 5% in dividends, and their payouts look safe. These companies have strong fundamentals, which can make them ideal investments to hold for the long term. 10 stocks we like better than Pfizer › Dividend income offers a great way to strengthen your overall financial position. It can potentially make you less dependent on the income you earn from a job, maybe even allowing you to work less or retire earlier than planned. Money doesn't buy happiness, but being less dependent on work to fund your lifestyle could be a contributor to a happier, less stressful life. A great way to build up dividend income is to invest in high-yielding dividend stocks that also happen to be lower-risk investments. Pfizer (NYSE: PFE), Realty Income (NYSE: O), and Bank of Nova Scotia (NYSE: BNS) are three attractive investments that you'll want to consider if you want to create a strong portfolio of income-generating stocks. If you're looking for a high-yielding stock to hold for the long term, Pfizer is one you'll want to strongly consider. At 7.4%, its yield right now is more than five times what you'd get with the average stock on the S&P 500, which pays about 1.3%. Pfizer's stock is trading down more than 10% this year (as of the end of last week), as it can't seem to catch a break. While its valuation is modest -- it trades at 17 times its trailing earnings -- concerns about healthcare reform and the company's future growth prospects have made investors uneasy about the business and investing in it. But the healthcare company is still doing well and is on track to hit its guidance, which calls for revenue between $61 billion and $64 billion this year (comparable to how it did last year). It is also slashing costs to improve its bottom line. And it has been less than two years since it acquired oncology company Seagen, which may unlock more long-term growth for Pfizer in the future. Last year, the company also obtained approval from regulators for its first gene therapy in the U.S. -- Beqvez, a treatment for a genetic bleeding disorder. There's some uncertainty and risk with Pfizer, but there are opportunities as well. And at such a modest valuation, now can be an excellent time to add it to your portfolio. Pfizer has been a big name in healthcare for decades, and I don't think that's likely to change anytime soon. One dividend stock I think all income investors should consider owning is Realty Income. This is a real estate investment trust (REIT) that not only offers a high yield of 5.8%, but it also pays a dividend every month. There's no need to wait around for multiple months, as is the case with other dividend stocks; with Realty Income, you're getting a much more regular stream of cash flow. The REIT has a diverse mix of tenants, which makes it an ideal option for long-term investors. It's diversified across industries and geographies, with more than 1,500 clients across 91 industries. The dividend remains well supported -- the REIT reported funds from operations (FFO) per share of $1.05 during the first three months of the year (versus $0.94 a year ago). That averages out to $0.35 per share per month, which is higher than the rate of its monthly dividend of $0.2685. REITs use FFO to assess how much they can afford to pay in dividends, and with Realty Income's financials looking solid, there aren't any significant risks with its payout. Share prices of Realty Income are up 5% this year, and this can be a great income-generating investment to add to your portfolio for the long haul. Rounding out this list of high-yielding dividend stocks is Canada-based Bank of Nova Scotia, also known as Scotiabank. At around 6%, that's a high payout for a top bank stock that is known for long-term stability. It declared its first dividend back in 1833 and has continued making regular payments since then. The bank increased its provision for credit losses in its most recent quarter, in a sign of growing concern about macroeconomic conditions. Scotiabank's net income totaled over $2 billion Canadian dollars for the period ending April 30, which was nearly identical to its bottom line in the prior-year period. There are concerns about how the Canadian economy may perform in the near future due to tariffs, but in the grand scheme of things, that may prove to be a short-term concern for investors who are willing to hang on for years. Scotiabank's impressive track record and resilience over the years should inspire some confidence in the business. The bank stock has increased its dividend by more than 22% in four years and can be an excellent option to hang on to for the long term. Not only can you collect a high yield today, but the dividend income you get from this investment can rise over the years. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer and Realty Income. The Motley Fool recommends Bank Of Nova Scotia. The Motley Fool has a disclosure policy. Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5% was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Elon Musk Net Worth Down $64 Billion In 2025 — But Tesla CEO Still Richer Than Value Of Ford, General Motors, Stellantis, Toyota Combined
The world's richest billionaire has taken a hit to his wealth in 2025. Even after a year-to-date decline for Tesla Inc (NASDAQ:TSLA) stock, Elon Musk is still significantly ahead of who is in second place and worth more than several of his automotive rivals combined. What Happened: Tesla CEO Elon Musk is the world's richest person and gets the majority of his net worth from ownership stakes in the electric vehicle company, SpaceX, xAI and other ventures. Musk currently ranks first as the world's richest with a wealth of $369 billion according to Bloomberg. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — This is significantly ahead of the billionaire in second place, Mark Zuckerberg, who is worth an estimated $245 billion. What's also interesting is that if you look at Musk's wealth, it's worth more than several of the largest automotive companies combined. Take this list, for example: Stellantis NV (NYSE:STLA): $29.7 billion Ford Motor Company (NYSE:F): $41.9 billion General Motors Company (NYSE:GM): $47.4 billion Toyota Motor Corporation (NYSE:TM): $238.2 billion Add it up and it's a value of $357.2 billion. That means Musk is worth more than these four automotive companies combined, with $11.8 billion left It's Important: Musk and Tesla have dominated the electric vehicle market in the U.S. and globally. Tesla is worth over $1 trillion, even with recent struggles with delivery figures and demand. A recent public feud between Musk and President Donald Trump sent shares of Tesla down significantly, marking the company's biggest one-day market capitalization loss of $152 billion. That drop also sent the wealth of Musk from $368 billion on June 4 to $335 billion on June 5. Tesla stock and Musk's wealth have rebounded from that feud-related sell-off. Tesla stock remains down 15.9% year-to-date. Musk's wealth has taken a hit in 2025 with a $63.5 billion drop in his net worth over the year. This comes with Tesla stock falling, while other ventures of his such as Neuralink, xAI and SpaceX are seeing higher valuations. Musk became the first person to have a net worth of more than $400 billion in late 2024 and he could be headed back to that figure if Tesla stock can rally on recent robotaxi news and turn positive on the year. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Elon Musk Net Worth Down $64 Billion In 2025 — But Tesla CEO Still Richer Than Value Of Ford, General Motors, Stellantis, Toyota Combined originally appeared on
Yahoo
41 minutes ago
- Yahoo
Urgent dried fruit recall in 19 states over serious health risk
Dried fruit sold in multiple states has been recalled due to a serious health risk. Turkana Food Inc issued a recall on 352 cases of its Floria Dried Apricots, according to a press release shared by the U.S. Food and Drug Administration on Thursday. The product was recalled because it contains an undeclared allergen, sulfites, or 'chemicals used as preservatives' added to foods, beverages, and medications to prevent them from spoiling, according to the Cleveland Clinic. According to the FDA, the recall came after routine sampling, performed by the New York State Department of Agriculture, revealed that the product contained sulfites, which 'were not listed on the product labeling.' As Turkana Food Inc continues an 'investigation to correct the issue with the manufacturer,' production and distribution of the product by the FDA has been ceased. The recalled Floria Dried Apricots were sold at stores in 19 states: Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Maryland, Michigan, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, Texas, and Virginia. The product has the LOT number 440090478-15-333 on the bottom portion of the packaging. The UPC Label 2539560010 is marked by a sticker on the side of the packaging. The expiration date of November 2026 is also on the bottom of the packaging. Consumers who have the recalled product should not consume it. The FDA is also urging consumer to return the dried apricots to the place of purchase for a full refund. There have been no reported illnesses so far. Most often, people with asthma have allergies and sensitivities to sulfites. Earlier this week, P. East Trading Corp. also urgently recalled its Salted Smoked Split Herring because it may have been contaminated with Clostridium botulinum, a bacterium that can cause illness or death. Botulism is a rare but serious condition caused by a toxin that attacks the body's nerves. Symptoms include general weakness, dizziness, double-vision, trouble with speaking or swallowing, difficulty in breathing, abdominal distension, and constipation. Then, on Tuesday, 6,668 cases of Breyers Chocolate Truffle Ice Cream was also recalled following customer concerns that there was a mislabeling error. The recall came after it was found that the tubs actually contained Rocky Road ice cream. The Chocolate Truffle flavor has an allergen label that reads, 'may contain tree nuts,' while the Rocky Road flavor declares almonds as one of the ingredients. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023.
